Refractory Erdheim-Chester disease
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB08881 | Vemurafenib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] |
| Drug | Drug Name | Phase | Status | Count |
|---|